Profile data is unavailable for this security.
About the company
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development and commercialization of therapies for debilitating rare and orphan diseases. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. It is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.
- Revenue in USD (TTM)224.00m
- Net income in USD-158.56m
- Incorporated2018
- Employees278.00
- LocationMirum Pharmaceuticals Inc950 Tower Ln Ste 1050FOSTER CITY 94404-4251United StatesUSA
- Phone+1 (650) 667-4085
- Fax+1 (302) 269-3855
- Websitehttps://mirumpharma.com/
More ▼
Mergers & acquisitions
| Acquired company | MIRM:NMQ since announced | Transaction value |
|---|---|---|
| Travere Therapeutics Inc-Bile Acid Product Portfolio | -8.46% | 445.00m |
Data delayed at least 15 minutes, as of May 31 2024 21:00 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ironwood Pharmaceuticals, Inc. | 413.55m | -1.05bn | 1.00bn | 267.00 | -- | -- | -- | 2.42 | -6.79 | -6.79 | 2.52 | -2.08 | 0.5189 | -- | 4.41 | 1,548,880.00 | -135.68 | -4.54 | -164.13 | -5.20 | -- | -- | -261.50 | -7.81 | -- | 8.27 | 1.96 | -- | 7.83 | 5.02 | -672.50 | -- | 160.10 | -- |
| Pharvaris NV | 0.00 | -115.20m | 1.02bn | 82.00 | -- | 2.62 | -- | -- | -2.58 | -2.58 | 0.00 | 7.24 | 0.00 | -- | -- | 0.00 | -40.45 | -36.09 | -43.50 | -38.27 | -- | -- | -- | -- | -- | -127.47 | 0.0005 | -- | -- | -- | -32.15 | -- | -- | -- |
| Arcturus Therapeutics Holdings Inc | 124.53m | -107.30m | 1.05bn | 180.00 | -- | 3.96 | -- | 8.39 | -4.02 | -4.02 | 4.66 | 9.81 | 0.2799 | -- | 2.08 | 691,811.10 | -24.12 | -19.66 | -31.37 | -24.90 | -- | -- | -86.16 | -77.55 | -- | -- | 0.00 | -- | -19.03 | 60.31 | -417.95 | -- | 14.44 | -- |
| Cassava Sciences Inc | 0.00 | -47.90m | 1.06bn | 29.00 | -- | 12.12 | -- | -- | -1.17 | -1.17 | 0.00 | 1.82 | 0.00 | -- | -- | 0.00 | -25.63 | -30.74 | -33.88 | -32.12 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.50 | -- | -- | -- |
| Enliven Therapeutics Inc | 0.00 | -79.60m | 1.06bn | 46.00 | -- | 3.32 | -- | -- | -1.93 | -1.93 | 0.00 | 6.79 | 0.00 | -- | -- | 0.00 | -24.66 | -42.26 | -26.11 | -46.62 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4,910.75 | -- | -- | -- |
| Collegium Pharmaceutical Inc | 566.92m | 93.29m | 1.08bn | 197.00 | 16.10 | 4.88 | 4.52 | 1.91 | 2.06 | 2.06 | 12.06 | 6.79 | 0.4869 | 7.07 | 3.20 | 2,877,782.00 | 8.01 | 2.79 | 12.70 | 4.80 | 60.01 | 50.88 | 16.46 | 5.16 | 1.14 | 3.10 | 0.7372 | 0.00 | 22.17 | 15.11 | 292.60 | -- | -54.77 | -- |
| Prothena Corporation PLC | 89.25m | -172.40m | 1.12bn | 173.00 | -- | 2.23 | -- | 12.54 | -3.25 | -3.25 | 1.63 | 9.35 | 0.1308 | -- | -- | 515,901.70 | -25.26 | -14.20 | -27.09 | -15.11 | -- | -- | -193.17 | -111.02 | -- | -- | 0.00 | -- | 69.50 | 148.98 | -25.72 | -- | 9.71 | -- |
| Mirum Pharmaceuticals Inc | 224.00m | -158.56m | 1.13bn | 278.00 | -- | 4.82 | -- | 5.06 | -3.82 | -3.82 | 5.19 | 4.99 | 0.4546 | 4.24 | 5.62 | 848,477.30 | -32.18 | -38.93 | -38.17 | -44.88 | 73.26 | -- | -70.79 | -190.71 | 3.47 | -- | 0.5667 | -- | 141.85 | -- | -20.45 | -- | 21.81 | -- |
| AbCellera Biologics Inc | 35.79m | -146.90m | 1.15bn | 586.00 | -- | 1.02 | -- | 32.21 | -0.5056 | -0.5056 | 0.1232 | 3.85 | 0.0242 | -- | 1.32 | 61,071.67 | -9.92 | 6.08 | -10.62 | 6.67 | -- | -- | -410.47 | 24.69 | 7.75 | -- | 0.00 | 0.00 | -92.17 | 33.91 | -192.35 | -- | 70.96 | -- |
| Day One Biopharmaceuticals Inc | 0.00 | -208.94m | 1.16bn | 174.00 | -- | 3.91 | -- | -- | -2.50 | -2.50 | 0.00 | 3.40 | 0.00 | -- | -- | 0.00 | -64.27 | -- | -69.93 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -32.87 | -- | -- | -- |
| Ginkgo Bioworks Holdings Inc | 208.70m | -853.81m | 1.17bn | 1.22k | -- | 1.09 | -- | 5.60 | -0.4347 | -0.4347 | 0.1061 | 0.4855 | 0.1044 | -- | 3.82 | 171,344.00 | -42.70 | -- | -46.94 | -- | 80.43 | -- | -409.12 | -- | -- | -- | 0.00 | -- | -47.36 | -- | 57.58 | -- | -- | -- |
| 4D Molecular Therapeutics Inc | 20.45m | -104.56m | 1.24bn | 171.00 | -- | 2.04 | -- | 60.59 | -2.36 | -2.36 | 0.4841 | 11.74 | 0.0468 | -- | -- | 139,136.00 | -23.93 | -32.67 | -24.71 | -34.90 | -- | -- | -511.20 | -617.15 | -- | -- | 0.00 | -- | 562.29 | 7.96 | 6.19 | -- | 46.26 | -- |
| Tarsus Pharmaceuticals Inc | 42.56m | -148.21m | 1.25bn | 244.00 | -- | 4.52 | -- | 29.26 | -4.72 | -4.72 | 1.35 | 7.29 | 0.1519 | -- | 2.63 | 174,430.30 | -52.88 | -31.56 | -58.73 | -33.82 | 92.37 | -- | -348.22 | -242.59 | 7.92 | -- | 0.0981 | -- | -32.42 | -- | -118.86 | -- | 279.39 | -- |
Data as of May 31 2024. Currency figures normalised to Mirum Pharmaceuticals Inc's reporting currency: US Dollar USD
52.53%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BVF Partners LPas of 31 Mar 2024 | 4.37m | 9.27% |
| Eventide Asset Management LLCas of 31 Mar 2024 | 3.30m | 7.00% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 2.82m | 5.99% |
| Janus Henderson Investors US LLCas of 31 Mar 2024 | 2.75m | 5.83% |
| Cadian Capital Management LPas of 31 Mar 2024 | 2.29m | 4.86% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 2.25m | 4.78% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 2.14m | 4.53% |
| Rock Springs Capital Management LPas of 31 Mar 2024 | 1.86m | 3.94% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 1.58m | 3.36% |
| Citadel Advisors LLCas of 31 Mar 2024 | 1.39m | 2.95% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
